Download PDF
Semin intervent Radiol 2016; 33(04): 337-341
DOI: 10.1055/s-0036-1592319
Morbidity & Mortality
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt

Benjamin V. Park
1   Department of Radiology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
,
Ron C. Gaba
1   Department of Radiology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
,
R. Peter Lokken
1   Department of Radiology, University of Illinois Hospital and Health Sciences System, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
31 October 2016 (online)

Also available at
    Permissions and Reprints

Adverse events related to hepatic ischemia may occur after transarterial chemoembolization (TACE) and are noted more frequently in patients with portosystemic shunts. The presented case describes hepatic infarction after drug-eluting embolic (DEE) TACE in a patient with a large, presumably congenital portosystemic shunt. The authors will discuss risk factors for adverse outcomes after TACE in the setting of portosystemic shunts and present strategies to minimize such complications.

 

  • References

  • 1 Bruix J, Sherman M ; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3) 1020-1022
    CrossrefPubMedGoogle Scholar
  • 2 Tarazov PG, Polysalov VN, Prozorovskij KV, Grishchenkova IV, Rozengauz EV. Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 2000; 41 (2) 156-160
    CrossrefPubMedGoogle Scholar
  • 3 Fujiwara H, Kanazawa S, Hiraki T , et al. Hepatic infarction following abdominal interventional procedures. Acta Med Okayama 2004; 58 (2) 97-106
    PubMedGoogle Scholar
  • 4 Raoul JL, Sangro B, Forner A , et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37 (3) 212-220
    CrossrefPubMedGoogle Scholar
  • 5 A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 1995; 332 (19) 1256-1261
    CrossrefPubMedGoogle Scholar
  • 6 Garwood ER, Fidelman N, Hoch SE, Kerlan Jr RK, Yao FY. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl 2013; 19 (2) 164-173
    CrossrefPubMedGoogle Scholar
  • 7 Hsin IF, Hsu CY, Huang HC , et al. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol 2011; 45 (6) 556-562
    CrossrefPubMedGoogle Scholar
  • 8 Boulin M, Adam H, Guiu B , et al. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. Dig Liver Dis 2014; 46 (4) 358-362
    CrossrefPubMedGoogle Scholar
  • 9 Bouvier A, Ozenne V, Aubé C , et al. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011; 21 (8) 1719-1726
    CrossrefPubMedGoogle Scholar
  • 10 Jin B, Wang D, Lewandowski RJ , et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol 2011; 196 (4) 919-928
    CrossrefPubMedGoogle Scholar
  • 11 Tesdal IK, Wikström M, Flechtenmacher C, Filser T, Dueber C. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol 2006; 29 (5) 778-784
    CrossrefPubMedGoogle Scholar
  • 12 Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012; 53 (5) 545-550
    CrossrefPubMedGoogle Scholar
  • 13 Wang Z, Zhang H, Zhao H , et al. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol 2014; 20 (6) 487-491
    CrossrefPubMedGoogle Scholar
  • 14 Miura JT, Rilling WS, White SB , et al. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB (Oxford) 2015; 17 (8) 707-712
    CrossrefPubMedGoogle Scholar
  • 15 Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan Jr RK. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. J Vasc Interv Radiol 2013; 24 (1) 68-73
    CrossrefPubMedGoogle Scholar
  • 16 Gaba RC, Rim CM, Parvinian A. Re: Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong?. J Vasc Interv Radiol 2013; 24 (7) 1075-1076
    CrossrefPubMedGoogle Scholar
  • 17 Lammer J, Malagari K, Vogl T , et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33 (1) 41-52
    CrossrefPubMedGoogle Scholar
  • 18 van Malenstein H, Maleux G, Vandecaveye V , et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011; 34 (7) 368-376
    CrossrefPubMedGoogle Scholar
  • 19 Gorodetski B, Chapiro J, Schernthaner R , et al. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2016;
    PubMedGoogle Scholar
  • 20 Kuo YC, Kohi MP, Naeger DM , et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol 2013; 36 (5) 1336-1343
    CrossrefPubMedGoogle Scholar
  • 21 Padia SA, Chewning RH, Kogut MJ , et al. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol 2015; 38 (4) 913-921
    CrossrefPubMedGoogle Scholar
  • 22 Park JK, Al-Tariq QZ, Zaw TM, Raman SS, Lu DS. Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma in Patients with Transjugular Intrahepatic Portosystemic Shunts. Cardiovasc Intervent Radiol 2015; 38 (5) 1211-1217
    CrossrefPubMedGoogle Scholar
  • 23 Donahue LA, Kulik L, Baker T , et al. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 2013; 24 (1) 74-80
    CrossrefPubMedGoogle Scholar